

The logo for GRAIL, with the letters G, R, A, and I in a standard font, and the letter L in a larger, bold font. The background of the logo is a dark purple with a faint, glowing, spherical molecular or cellular structure.

---

DETECTING  
CANCER IN  
COLORADO  
EARLY, WHEN  
IT CAN BE  
CURED

---

Detecting cancer in earlier stages, before it has spread throughout the body, enables more successful treatment and saves lives. This fact has made cancer screening tests among the most important advances in the War on Cancer. **But the important benefits of early cancer detection reach too few Americans.**

Cancer is the second leading cause of death in America, and claims the lives of nearly 1,700 Americans every day. It is estimated that **more than 8,420 Coloradans will die of cancer in 2021.**<sup>1</sup>

Finding cancer earlier can reduce the human and economic toll of cancer. The five-year cancer survival rate when diagnosed earlier – before cancer has spread within the body – is 89%, compared to 21% when it is detected after the cancer has spread.

**In the U.S., cancers with routine screening tests account for just 29 percent of cancer deaths, leaving the majority of cancers without an early detection test.**<sup>3</sup>

In 2021, 6 of the top 10 causes of cancer death in Colorado have no recommended screening test.


1. <https://cancerstatisticscenter.cancer.org/#1/state/Colorado>
2. <https://statecancerprofiles.cancer.gov/quick-profiles/index.php?tabSelected=2&statername=colorado>
3. Source: Data on file from SEER 18 Regs Research Data, Nov 2017 Sub. Includes persons aged 50-79. Estimated deaths per year in 2020 from ACS Cancer Facts and Figures Report 2020. Recommended screening tests include breast, cervical, colorectal, and high-risk lung cancer

**Top 10 Estimated Causes of Cancer Deaths in Colorado, 2021<sup>1</sup>**

Cancer	Estimated Deaths
Lung and bronchus	1,290
Colorectum	700
Breast (female)	690
Pancreas	660
Prostate	560
Liver	420
Brain	300
Leukemia	300
Non-hodgkin lymphoma	270
Urinary bladder	260

GRAIL, an innovative healthcare company, is developing a multi-cancer early detection blood test that complements existing screenings. GRAIL’s blood-based technology has detected and localized more than types of 50 cancer types, across stages. This technology will enable cancer detection earlier for a larger number of patients in Colorado, when treatment may be more effective and less costly.

**COLORADO CLINICAL TRIAL SITES**



Rocky Mountain Cancer Centers, LLP (12 sites)

With more than 110,000 participants enrolled to date, including those enrolled through Rocky Mountain Cancer Centers, the company’s ambitious clinical study program is among the largest in genomic medicine.

**Together, we can help save the lives of Coloradans.**